{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:59:38Z","timestamp":1776988778842,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Glaxo-Smith Kline"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.lungcan.2014.08.011","type":"journal-article","created":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T21:43:32Z","timestamp":1409089412000},"page":"288-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy"],"prefix":"10.1016","volume":"86","clinical-trial-number":[{"clinical-trial-number":"nct01208064","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01262820","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jared M.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza C.","family":"Villaruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Socinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juneko","family":"Grilley-Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirav","family":"Dhruva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Stinchcombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lungcan.2014.08.011_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"9856","key":"10.1016\/j.lungcan.2014.08.011_bib0010","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(12)60919-2","article-title":"Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions","volume":"380","author":"Soerjomataram","year":"2012","journal-title":"Lancet"},{"issue":"36","key":"10.1016\/j.lungcan.2014.08.011_bib0015","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.1200\/JCO.2009.23.5622","article-title":"American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer","volume":"27","author":"Azzoli","year":"2009","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.lungcan.2014.08.011_bib0020","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.lungcan.2014.08.011_bib0025","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.lungcan.2014.08.011_bib0030","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdq020","article-title":"Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)","volume":"21","author":"Reck","year":"2010","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.lungcan.2014.08.011_bib0035","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","article-title":"Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil","volume":"27","author":"Reck","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2014.08.011_bib0040","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10456-014-9420-y","article-title":"Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions","volume":"17","author":"Vasudev","year":"2014","journal-title":"Angiogenesis"},{"issue":"19","key":"10.1016\/j.lungcan.2014.08.011_bib0045","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1200\/JCO.2009.23.9749","article-title":"Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage I\/II resectable non-small-cell lung cancer","volume":"28","author":"Altorki","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2014.08.011_bib0050","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.lungcan.2014.08.011_bib0055","unstructured":"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01208064 [accessed 28.04.14]."},{"key":"10.1016\/j.lungcan.2014.08.011_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"issue":"17","key":"10.1016\/j.lungcan.2014.08.011_bib0065","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1200\/JCO.2011.39.2993","article-title":"Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial","volume":"30","author":"Scagliotti","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.lungcan.2014.08.011_bib0070","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1200\/JCO.2011.41.4987","article-title":"International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin\/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1","volume":"30","author":"Scagliotti","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.lungcan.2014.08.011_bib0075","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1200\/JCO.2009.26.1321","article-title":"Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer","volume":"28","author":"Scagliotti","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.lungcan.2014.08.011_bib0080","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","article-title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial","volume":"11","author":"Herbst","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2014.08.011_bib0085","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","article-title":"Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial","volume":"15","author":"Reck","year":"2014","journal-title":"Lancet Oncol"},{"issue":"Suppl.","key":"10.1016\/j.lungcan.2014.08.011_bib0090","article-title":"Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy","volume":"31","author":"Hanna","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.lungcan.2014.08.011_bib0095","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.2010.29.5717","article-title":"Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial","volume":"29","author":"de Boer","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214003560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500214003560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T08:56:18Z","timestamp":1538297778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500214003560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S0169500214003560"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.08.011","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2014.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}